

		Teaching Guide		
	Identifying Data			2022/23
Subject (*)	Medicinal Chemistry Code			610509116
Study programme	Mestrado Universitario en Investi	gación Química e Química Ind	ustrial (Plan 2020)	L.
		Descriptors		
Cycle	Period	Year	Туре	Credits
Official Master's Degree	e 2nd four-month period	First	Optional	3
Language	SpanishEnglish			
Teaching method	Face-to-face			
Prerequisites				
Department	Departamento profesorado máste	erQuímica		
Coordinador	Riveiros Santiago, Ricardo E-mail ricardo.riveiros@udc.es		udc.es	
Lecturers	Brea Fernández, Roberto Javier	ández, Roberto Javier E-mail roberto.brea@udc.es		c.es
	Criado Fernández, Alejandro		a.criado@udc.es	
	Riveiros Santiago, Ricardo		ricardo.riveiros@udc.es	
Web	http://www.usc.es/gl/centros/quim	nica/curso/master.html		
General description	This subject aims that the student	ts acquire the basic concepts i	n the field of medicinal che	mistry and drug design, and also
	know the required steps for drug	development, ranging from the	discovery of an active con	npound in the laboratory to its
	integration into the market. The s	ubject will also address the ma	ijor current methodologies	in finding lead compounds that
	are employed in both industrial and academic level, and its optimization for the development of a drug. This includes fro			ent of a drug. This includes from
	structure-based desigh, virtual sc	reening, to fragment-based de	sign of compounds. The m	ost relevant aspects in the
	quantification oof the structure-re	lationships (QSAR) will be also	described. Each of the co	ntents of this subject will be
	illustrated by representative exam	nples.		

	Study programme competences
Code	Study programme competences
A1	Define concepts, principles, theories and specialized facts of different areas of chemistry.
A2	Suggest alternatives for solving complex chemical problems related to the different areas of chemistry.
A3	Innovate in the methods of synthesis and chemical analysis related to the different areas of chemistry
A4	Apply materials and biomolecules in innovative fields of industry and chemical engineering.
B1	Possess knowledge and understanding to provide a basis or opportunity for originality in developing and / or applying ideas, often within a
	research context
B2	Students should apply their knowledge and ability to solve problems in new or unfamiliar environments within broader (or multidisciplinary)
	contexts related to their field of study.
B4	Students should be able to communicate their conclusions, and the knowledge and the reasons that support them to specialists and
	non-specialists in a clear and unambiguous manner
B7	Identify information from scientific literature by using appropriate channels and integrate such information to raise and contextualize a
	research topic
B10	Use of scientific terminology in English to explain the experimental results in the context of the chemical profession
B11	Apply correctly the new technologies to gather and organize the information to solve problems in the professional activity.
C1	CT1 - Elaborar, escribir e defender publicamente informes de carácter científico e técnico
C3	CT3 - Traballar con autonomía e eficiencia na práctica diaria da investigación ou da actividade profesional.
C4	CT4 - Apreciar o valor da calidade e mellora continua, actuando con rigor, responsabilidade e ética profesional.

Learning outcomes	
Learning outcomes	Study programme
	competences



To know the main concepts in medicinal chemistry and drug design: therapeutic targets, enzimatic inhibitors, agonists,	AC1	BC1	CC1
antagonists, optimal pharmacological properties, etc.	AC2	BC2	CC3
	AC3	BC4	CC4
	AC4	BC7	
		BC10	
		BC11	
To know the required steps for drug development, starting from the discovery of an active compound in the laboratory till its	AC1	BC1	CC1
integration into the market.	AC2	BC2	CC3
	AC3	BC4	CC4
	AC4	BC7	
		BC10	
		BC11	
To know the main methodologies for the seaching of active molecules (hits) and their optimization for the development of a	AC1	BC1	CC1
new drug. Since the design based on the 3D structure of the therapeutic target, the real and virtual screening of libraries or the	AC2	BC2	CC3
fragment based design.	AC3	BC4	CC4
	AC4	BC7	
		BC10	
		BC11	

	Contents
Торіс	Sub-topic
Chapter 1. General aspects, definitions and concepts	Drug discovery: historical perspective. Drug activity phases. Enzymatic catalysis.
	Definitions and concepts: agonist, antagonist, transition state analogs, reversible
	inhibition (competitive, non-competitive), irreversible inhibition, suicide substrates.
	Examples.
Chapter 2. Therapeutic targets	Therapeutic targets: classification and their main characteristics. Enzymes. Membrane
	transporters. Voltage-gated ion channels. Non-selective cation channels. Receptors
	with intrinsic ion channels. Receptors with intrinsic enzymatic activity. Receptors
	coupled to various cytosolic proteins. G-protein-coupled receptors. Nuclear receptors.
Chapter 3. Strategies for drug discovery I. Structure-based	Evolution of the structure-based design in drug discovery. Practical aspects of the
design	determination of the three dimensional structure of a target-X-ray crystallography for
	the structure-based design. Applications of NMR spectroscopy in the rational design.
	Docking. Molecular dynamics simulations. QM/MM. Examples.
Chapter 4. Strategies for drug discovery II. Virtual screening	Basics of the virtual screening candidates. Available databases. Applications:
and fragment-based design	identifying ligands for a target or potential targets of a ligand. Basics of the
	fragment-based design. Screening of candidates by X-ray crystallography. Other
	biophysical screening methods. Examples.
Chapter 5. Hit Compound optimization. QSAR studies	Molecular modifications based on isosteric replacement. Conformational restriction
	and steric hindrance in medicinal chemistry. Homo and heterodimeric ligands.
	Prodrugs. Quantification of Structure-Activity Relationship (QSAR).

	Planning	9		
Methodologies / tests	Competencies	Ordinary class	Student?s personal	Total hours
		hours	work hours	
Guest lecture / keynote speech	A1 A2 A4 A3 B1 B2	12	24	36
	B4 B7 B10 B11			
Seminar	A1 A2 A4 A3 B1 B2	7	18	25
	B4 B7 B10 B11 C1			
	C3 C4			
Supervised projects	B1 B2 B4 B7	2	4	6



Objective test	A1 A4 A3 B1 B10	2	4	6
Personalized attention		2	0	2

(*)The information in the planning table is for guidance only and does not take into account the heterogeneity of the students.

	Methodologies
Methodologies	Description
Guest lecture /	It will be held 12 sessions of lectures by videoconference in one group, where the theoretical contents of the course will be
keynote speech	associated with illustrative examples. It will consist mainly in PowerPoint presentations. Copies of these presentations will be
	available for the students in advance via the Moodle platform of the course. This will allow the students to study ahead the
	contents of the course and to facilitate the monitoring of explanations.
Seminar	Seven sessions in small group seminars are scheduled. In these seminars, students will solve practical exercises
	(interpretation and processing information using specialized software and internet, evaluation of scientific papers, etc.), will
	prepare reports related to the different subjects and will present them during the class, followed by a discussion section with
	the professor and the rest of students. Students will have in advance the information they need via the Moodle platform.
	Attendance at these classes is mandatory.
Supervised projects	There will be tutorial seasons scheduled by the teacher and coordinated by the center. Activities such as supervision of
	directed works, clarification of doubts are proposed. Attendance at these tutorials will be compulsory.
Objective test	It will be an objective test that will cover the entire contents of the subject.

Description
Students must review the theoretical concepts introduced in each chapter using the reference manual and the material
provided by the professor. Those students, which have significant difficulties to do the proposed activities, should contact with
he professor during the tutorials, in order to analyze the problems and to receive the necessary support.
The professor will analyze with those students who do not successfully pass the evaluation, and so wish, their difficulties in
earning the course content. Additional material (questions, exercises, tests, etc.) to strengthen the learning of the course
night also provided.
Students with appreciation a part-time academic and attendance waiver of exemption may complete the seminars in individua
and/or group tutoring schedule to be agreed with the teachers. The activities undertaken in these tutorials will be similar to
hose of students in ordinary regime and consideration for the final assessment.
:h Ti e m Si

		Assessment	
Methodologies	Competencies	Description	Qualification
Seminar	A1 A2 A4 A3 B1 B2 B4 B7 B10 B11 C1 C3 C4	Continuous assessment will be the 40% of the final assessment of the subject. It will have two components: interactive classes in small group (seminars) and interactive classes in very small group (tutorials). Seminars and tutorials will include solving of proposed exercises and practical cases (10%), writing reports (10%), oral presentations [(works, reports, problems, practical cases), 10%] and oral questions along the course (10%). It can take place in the classroom or by telematic media.	40
Objective test	A1 A4 A3 B1 B10	The objective test or final exam (N2) will focus on the entire contents of the subject, and will take place in the classroom.	60

Assessment comments



The assestment of the matter will have two components: Continuous assestment and a final exam or objective test. To access to the objective test the student must assist in, at least, 80% of the mandatory classroom teaching activities (seminars and tutorials). The student's final qualification will be calculated applying this formula:

Final qualification = $0.4 \times N1 + 0.6 \times N2$. N1 is the numeric qualification corresponding to the continuous assessment (scale 0-10) and N2 is the numeric qualification corresponding to the objective test (scale 0-10).

Students who study the subject for a second time will have the same system of class attendance and assestment than those who study the course for first time.

In the case of students with recognition of part-time dedication and academic assistance waiver, the qualification of the continuous assessment will be replaced by that obtained in the personal tutorials. Students who attend less than 25% of planned academic activities and do not assist to the objective test, will be qualified as "Not presented".

	Sources of information
Basic	- Camille Georges Wermuth (2008). The practice of medicinal chemistry, 3rd Ed. Amsterdam: Elsevier
	- Graham L. Patrick (2013). An introduction to medicinal chemistry, 5th Ed. Oxford: Oxford University Press
Complementary	- E. J. Corey, B. Czakó, L. Kürti (2007). Molecules and medicine. New Jersey: John Wiley and Sons
	- K. C. Nicolaou, T. Montagnon, Eds. (2008). Molecules that changed the world. Weinheim: Wiley-VCH
	- Edward R. Zartler & amp; Michael J. Shapiro, Eds. (2008). Fragment-based drug discovery, a practical approach.
	Chichester: John Wiley & amp; amp; Sons
	- Celerino Abad Zapatero (2013). Ligand efficiency indices for drug discovery. Amsterdam: Elsevier

Recommendations
Subjects that it is recommended to have taken before
/
Subjects that are recommended to be taken simultaneously
Subjects that continue the syllabus
Other comments
It is very important to attend the expository classes. It is essential to keep the study of the subject up to date. After reading a topic in the reference
manual, it is useful to sumarize the important points (see summary of important concepts in the reference manual). It is recommended to read the

specific bibliography for each topic that will help a better understanding of the key concepts.

(*)The teaching guide is the document in which the URV publishes the information about all its courses. It is a public document and cannot be modified. Only in exceptional cases can it be revised by the competent agent or duly revised so that it is in line with current legislation.